Qubio builds AI software that transforms neuroimaging into objective, quantified biomarkers — giving clinicians a reliable second opinion on some of the most complex diseases to diagnose.

Our platform, Neurocloud, automates the analysis of PET, MRI and SPECT studies, delivering a full quantitative report in minutes. No subjectivity. No inter-observer variability. Just reproducible data that neurologists, radiologists and nuclear medicine physicians can act on with confidence.

What we analyse:
- PET — amyloid quantification in Centiloid scale, FDG metabolism and dopaminergic studies
- MRI — brain atrophy, white matter lesions and longitudinal follow-up (Multiple Sclerosis, dementia)
- SPECT — perfusion and dopaminergic studies (Parkinsonisms)
- SISCOM — ictal/interictal subtraction for refractory epilepsy surgical planning

Where we are:
- 40+ hospitals across Spain, Portugal, Italy and Brazil
- Integrated in platforms including Claritas
- CE marked | ANVISA Brazil | FDA clearance in progress
- Spin-off of the University Hospital of Santiago de Compostela (CHUS)

Beyond clinical practice:
We collaborate with pharma companies on research, clinical studies and commercial partnerships — always with one focus: better outcomes for patients.

Neurocloud integrates invisibly into existing clinical workflows — compatible with PACS, deployable on cloud, on-premise or hybrid — with full data privacy compliance.

We started with a clear goal: bring the precision of quantitative neuroimaging to real clinical practice, at a cost that makes it accessible.

Augmented Neuroimaging. That's Qubio.

Qubio NeurocloudⓇ

Org chart

Teams

Offices

Qubio NeurocloudⓇ

Org chart

Teams

Offices

Related companies